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Systemic sclerosis (SSc) is an autoimmune disease character-
izedbywidespreadﬁbrosisaﬀectingtheskin,internalorgans,
and vasculature. Vascular disease with intimal proliferation
and obliterative vasculopathy is extremely prevalent in SSc,
most commonly manifesting as Raynaud’s phenomenon and
digital ulcerations. Other manifestations of vascular disease
occur less frequently in patients with SSc, including ischemic
digital loss, pulmonary arterial hypertension (PAH), and
renalcrisis.VasculardiseaseinSScmayalsocommonlyaﬀect
pregnancy outcomes and sexual function. Finally, patients
with SSc can rarely suﬀer from inﬂammatory vasculitis, and
recognition of this has a signiﬁcant impact on therapy. In
this special issue on vascular disease in systemic sclerosis, we
invitedoriginalresearcharticlesandreviewarticlesregarding
the pathogenesis, epidemiology, natural history, evaluation,
and/or management of vascular complications in patients
with SSc.
The ﬁrst paper of this special issue describes the vascular
microenvironmentthatlikelycontributestothepathogenesis
of vasculopathy in SSc. This is followed by two papers of the
current knowledge regarding the pathogenesis, evaluation,
and management of digital ulcers and digital ischemic loss in
patients with SSc. The fourth paper of the special issue is an
original research article that describes the prevalence of and
risk factors for nondigital lower extremity ulcers in SSc. The
authors found that antiphospholipid antibodies and genetic
prothromboticmutationsarehighlyprevalentinSScpatients
with lower extremity ulcers. The next paper describes the
utility of registries in understanding the natural history
of digital ulcers and discusses the need for classiﬁcation
criteria for the assessment of digital ulcers. This is followed
by a review article discussing the potential use of nailfold
videocapillaroscopy as an outcome measure in clinical trials
forpatientswithSScandvascularcomplications,particularly
digital ulcers and PAH.
The next section of the special issue relates to cardiopul-
monary vascular complications in SSc, with a particular
focus on PAH and right ventricular failure. The ﬁrst paper in
this section describes a case report of a patient with mixed
connective tissue disease and severe, refractory PAH who
experienced dramatic improvement in functional ability and
hemodynamics in response to treatment with tocilizumab, a
humanized monoclonal antibody to the human interleukin-
6 receptor. This is followed by an original research article
evaluating the relationship of serum endoglin levels in
patients with and without elevated systolic pulmonary
arterial pressures (sPAP) on echocardiography. This study
found that SSc patients with and without elevated sPAP
had much higher levels of serum endoglin compared
with healthy controls, suggesting that endoglin may be a
potential biomarker of vasculopathy that is not speciﬁc
to the pulmonary vasculature. The next paper describes
a histopathogic comparison of samples from the right
ventricle of patients with SSc-associated PAH and idiopathic
PAH (IPAH). The authors found that the right ventricular
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more inﬂammatory inﬁltrates than those from patients with
IPAH, but the degree of interstitial ﬁbrosis was similar in
the two groups. The ﬁnal paper in this section is a review
describing available nuclear cardiology imaging modalities
that may be useful in the assessment of early vascular disease
and myocardial damage in patients with SSc.
The next section of the special issue is focused on renal
manifestations of SSc. The ﬁrst paper reviews the types of
renal involvement seen in SSc and the potential utility of
screening patients for subclinical renal disease. The next
paper describes the histopathologic ﬁndings characteristic of
scleroderma renal crisis (SRC) and the potential role of renal
biopsies in predicting prognosis. Finally, an original research
article describes the methodology and preliminary data
of an international web-based prospective study designed
to determine if the use of angiotensin converting enzyme
inhibitors prior to the onset of SRC is associated with worse
outcomes.
The subsequent section of the special issue addresses the
eﬀects of vascular disease on pregnancy and sexual function
in patients with SSc. The ﬁrst paper reviews the published
literature regarding the eﬀects of vascular complications,
such as PAH and SRC, on pregnancy outcomes in patients
with SSc. This is followed by review articles focusing on
sexual dysfunction in patients with SSc, including male
erectile dysfunction and female sexual arousal disorder.
These papers also address the role of phosphodiesterase-
5 inhibitors in the treatment of SSc patients with sexual
dysfunction.
The ﬁnal section includes two papers describing the
known data on inﬂammatory vasculitis in patients with SSc.
The ﬁrst focuses on microscopic polyangiitis, while the latter
article reviews the literature regarding small, medium, and
large vessel vasculitis in SSc.
In summary, this special issue provides a comprehensive
compilation of articles with novel information relevant to
the topic of vascular disease in SSc. The papers included
herein provide the framework for the current and future
developmentofimportantbiomarkers,outcomeassessments
for clinical trials, and novel therapeutic modalities for
patients with SSc and vascular complications. We, the guest
editors, hope that readers ﬁnd this information useful in the
care of patients with SSc.
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